89bio, Inc.
ETNB
$18.88
$0.653.57%
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
--
Headlines
6/2/2023
-
Tickeron - Technical Analysis
6/2/2023
-
Tickeron - Technical Analysis
6/1/2023
-
Tickeron - Stocks
6/1/2023
-
Tickeron - Stocks
5/31/2023
-
PR Newswire
5/31/2023
-
Tickeron - Stocks
5/29/2023
-
Zacks Investment Research
5/28/2023
-
SeekingAlpha
5/27/2023
-
Tickeron - Stocks
5/26/2023
-
Tickeron - Stocks
5/25/2023
-
Ticker Report
Peter Kolchinsky-led RA Capital's New Positions Feature CureVac, Mineralys, Pilant, Enliven Therapeu
5/24/2023
-
24/7 Wall St.
5/23/2023
-
Seeking Alpha - Healthcare
5/23/2023
-
TipRanks Financial Blog
5/23/2023
-
Globe Newswire
5/23/2023
-
Tickeron - Technical Analysis
5/20/2023
-
Tickeron - Technical Analysis
5/19/2023
-
Zolmax
5/19/2023
-
Ticker Report
5/19/2023
-
Tickeron - Stocks
5/18/2023
-
SeekingAlpha
5/18/2023
-
Ticker Report
5/18/2023
-
Zolmax
5/18/2023
-
Tickeron - Technical Analysis
5/17/2023
-
Ticker Report
Income Statement
Total Revenue (TTM)
--
EBITDA (TTM)
EBIT (TTM)
Net Income (TTM)
Balance Sheet
Total Assets (Q)
Total Debt (Q)
Total Liabilities (Q)
Book Value Per Share (Q)
Cash Flow
Cash from Operations (TTM)
Cash from Investing (TTM)
Cash from Financing (TTM)
Net Change in Cash (TTM)
Filings
Filing Date
Monday, May 8, 2023
Period Date
Friday, March 31, 2023
Next Filing
Week of Aug 7 and 11 (est)
Price History
Beta
7-Day Total Return
30-Day Total Return
60-Day Total Return
90-Day Total Return
Year to Date Total Return
1-Year Total Return
2-Year Total Return
3-Year Total Return
5-Year Total Return
--
52-week Low
52-week High
Valuation
Enterprise Value
Price/Sales (TTM)
--
Price/Book (Q)
Dividends and Shares
Shares Outstanding
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
Phone Number
415-432-9270
Address
142 Sansome Street
San Francisco, CA 94104
San Francisco, CA 94104
Country
Year Founded
Business Description
Sector
89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. The company’s lead...
more
